ProPhase Labs, Inc. (PRPH)
USD 0.25
(-7.78%)
USD 0.25
(-7.78%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 91.92 Million USD | 4.88% |
| 2022 | 87.64 Million USD | -1.84% |
| 2021 | 89.29 Million USD | 184.33% |
| 2020 | 31.4 Million USD | 155.87% |
| 2019 | 12.27 Million USD | -40.81% |
| 2018 | 20.73 Million USD | -39.3% |
| 2017 | 34.16 Million USD | 166.84% |
| 2016 | 12.8 Million USD | -13.67% |
| 2015 | 14.82 Million USD | -7.65% |
| 2014 | 16.05 Million USD | -7.82% |
| 2013 | 17.42 Million USD | 4.56% |
| 2012 | 16.66 Million USD | -12.67% |
| 2011 | 19.07 Million USD | -12.06% |
| 2010 | 21.69 Million USD | 9.48% |
| 2009 | 19.81 Million USD | -18.68% |
| 2008 | 24.36 Million USD | -26.85% |
| 2007 | 33.31 Million USD | -4.39% |
| 2006 | 34.84 Million USD | -3.14% |
| 2005 | 35.97 Million USD | 14.1% |
| 2004 | 31.52 Million USD | 20.02% |
| 2003 | 26.26 Million USD | 5.35% |
| 2002 | 24.93 Million USD | 0.72% |
| 2001 | 24.75 Million USD | -4.99% |
| 2000 | 26.05 Million USD | -21.75% |
| 1999 | 33.3 Million USD | -31.48% |
| 1998 | 48.6 Million USD | -2.41% |
| 1997 | 49.8 Million USD | 3457.14% |
| 1996 | 1.4 Million USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 93.67 Million USD | 4.05% |
| 2024 Q1 | 90.03 Million USD | -2.06% |
| 2023 Q2 | 91.05 Million USD | -4.53% |
| 2023 Q4 | 91.92 Million USD | 0.24% |
| 2023 Q1 | 95.37 Million USD | 8.81% |
| 2023 FY | 91.92 Million USD | 4.88% |
| 2023 Q3 | 91.71 Million USD | 0.72% |
| 2022 Q4 | 87.64 Million USD | -10.45% |
| 2022 FY | 87.64 Million USD | -1.84% |
| 2022 Q3 | 97.87 Million USD | -0.07% |
| 2022 Q2 | 97.94 Million USD | -1.72% |
| 2022 Q1 | 99.66 Million USD | 11.61% |
| 2021 Q1 | 85.44 Million USD | 172.07% |
| 2021 FY | 89.29 Million USD | 184.33% |
| 2021 Q4 | 89.29 Million USD | 22.95% |
| 2021 Q3 | 72.63 Million USD | -4.84% |
| 2021 Q2 | 76.32 Million USD | -10.67% |
| 2020 Q1 | 11.86 Million USD | -3.31% |
| 2020 Q3 | 23.03 Million USD | 86.13% |
| 2020 Q4 | 31.4 Million USD | 36.35% |
| 2020 FY | 31.4 Million USD | 155.87% |
| 2020 Q2 | 12.37 Million USD | 4.27% |
| 2019 Q2 | 15.79 Million USD | -4.66% |
| 2019 Q1 | 16.57 Million USD | -20.08% |
| 2019 Q3 | 15.6 Million USD | -1.25% |
| 2019 Q4 | 12.27 Million USD | -21.33% |
| 2019 FY | 12.27 Million USD | -40.81% |
| 2018 Q3 | 20.57 Million USD | -7.0% |
| 2018 Q2 | 22.12 Million USD | -35.35% |
| 2018 Q1 | 34.22 Million USD | 0.17% |
| 2018 Q4 | 20.73 Million USD | 0.79% |
| 2018 FY | 20.73 Million USD | -39.3% |
| 2017 Q3 | 39.08 Million USD | -21.99% |
| 2017 FY | 34.16 Million USD | 166.84% |
| 2017 Q2 | 50.09 Million USD | -12.94% |
| 2017 Q1 | 57.54 Million USD | 349.48% |
| 2017 Q4 | 34.16 Million USD | -12.59% |
| 2016 Q2 | 11.54 Million USD | -13.37% |
| 2016 Q4 | 12.8 Million USD | 0.12% |
| 2016 Q3 | 12.78 Million USD | 10.77% |
| 2016 FY | 12.8 Million USD | -13.67% |
| 2016 Q1 | 13.32 Million USD | -10.14% |
| 2015 Q1 | 14.99 Million USD | -6.62% |
| 2015 FY | 14.82 Million USD | -7.65% |
| 2015 Q4 | 14.82 Million USD | 7.05% |
| 2015 Q3 | 13.85 Million USD | 15.06% |
| 2015 Q2 | 12.03 Million USD | -19.71% |
| 2014 Q4 | 16.05 Million USD | -10.4% |
| 2014 Q2 | 19.76 Million USD | 14.44% |
| 2014 Q1 | 17.26 Million USD | -0.88% |
| 2014 Q3 | 17.92 Million USD | -9.31% |
| 2014 FY | 16.05 Million USD | -7.82% |
| 2013 Q4 | 17.42 Million USD | 4.52% |
| 2013 Q3 | 16.66 Million USD | 10.62% |
| 2013 Q2 | 15.06 Million USD | -6.64% |
| 2013 Q1 | 16.13 Million USD | -3.13% |
| 2013 FY | 17.42 Million USD | 4.56% |
| 2012 FY | 16.66 Million USD | -12.67% |
| 2012 Q1 | 17.92 Million USD | -6.06% |
| 2012 Q2 | 15.17 Million USD | -15.33% |
| 2012 Q3 | 16.53 Million USD | 8.96% |
| 2012 Q4 | 16.66 Million USD | 0.77% |
| 2011 FY | 19.07 Million USD | -12.06% |
| 2011 Q1 | 19.88 Million USD | -8.32% |
| 2011 Q2 | 17.74 Million USD | -10.77% |
| 2011 Q3 | 20.31 Million USD | 14.49% |
| 2011 Q4 | 19.07 Million USD | -6.1% |
| 2010 Q2 | 19.84 Million USD | -10.51% |
| 2010 Q3 | 22.35 Million USD | 12.64% |
| 2010 Q1 | 22.17 Million USD | 11.92% |
| 2010 Q4 | 21.69 Million USD | -2.96% |
| 2010 FY | 21.69 Million USD | 9.48% |
| 2009 Q4 | 19.81 Million USD | 8.96% |
| 2009 Q2 | 16.49 Million USD | -23.76% |
| 2009 Q1 | 21.63 Million USD | -11.22% |
| 2009 Q3 | 18.18 Million USD | 10.26% |
| 2009 FY | 19.81 Million USD | -18.68% |
| 2008 Q3 | 26.57 Million USD | 3.97% |
| 2008 Q1 | 28.8 Million USD | -13.53% |
| 2008 Q2 | 25.55 Million USD | -11.28% |
| 2008 FY | 24.36 Million USD | -26.85% |
| 2008 Q4 | 24.36 Million USD | -8.29% |
| 2007 Q3 | 30.93 Million USD | 5.74% |
| 2007 FY | 33.31 Million USD | -4.39% |
| 2007 Q2 | 29.25 Million USD | -8.57% |
| 2007 Q1 | 31.99 Million USD | -8.17% |
| 2007 Q4 | 33.31 Million USD | 7.69% |
| 2006 Q2 | 28.7 Million USD | -10.04% |
| 2006 Q3 | 31.34 Million USD | 9.18% |
| 2006 Q4 | 34.84 Million USD | 11.18% |
| 2006 FY | 34.84 Million USD | -3.14% |
| 2006 Q1 | 31.91 Million USD | -11.3% |
| 2005 FY | 35.97 Million USD | 14.1% |
| 2005 Q4 | 35.97 Million USD | 14.05% |
| 2005 Q3 | 31.54 Million USD | 19.49% |
| 2005 Q2 | 26.39 Million USD | -13.41% |
| 2005 Q1 | 30.48 Million USD | -3.3% |
| 2004 Q4 | 31.52 Million USD | 38.03% |
| 2004 Q2 | 22.4 Million USD | -8.86% |
| 2004 Q1 | 24.58 Million USD | -6.41% |
| 2004 Q3 | 22.84 Million USD | 1.95% |
| 2004 FY | 31.52 Million USD | 20.02% |
| 2003 Q3 | 22.99 Million USD | 5.17% |
| 2003 Q1 | 22.72 Million USD | -8.84% |
| 2003 FY | 26.26 Million USD | 5.35% |
| 2003 Q2 | 21.86 Million USD | -3.78% |
| 2003 Q4 | 26.26 Million USD | 14.22% |
| 2002 Q1 | 22.36 Million USD | -9.64% |
| 2002 Q4 | 24.93 Million USD | -1.22% |
| 2002 Q3 | 25.24 Million USD | 2.02% |
| 2002 Q2 | 24.74 Million USD | 10.61% |
| 2002 FY | 24.93 Million USD | 0.72% |
| 2001 Q1 | 23.81 Million USD | -8.6% |
| 2001 Q2 | 22.95 Million USD | -3.59% |
| 2001 Q3 | 23.72 Million USD | 3.35% |
| 2001 Q4 | 24.75 Million USD | 4.32% |
| 2001 FY | 24.75 Million USD | -4.99% |
| 2000 Q4 | 26.05 Million USD | 3.2% |
| 2000 Q2 | 23.63 Million USD | -11.71% |
| 2000 Q1 | 26.76 Million USD | -19.62% |
| 2000 FY | 26.05 Million USD | -21.75% |
| 2000 Q3 | 25.24 Million USD | 6.83% |
| 1999 Q4 | 33.3 Million USD | 8.12% |
| 1999 Q3 | 30.8 Million USD | -1.91% |
| 1999 Q2 | 31.4 Million USD | -22.66% |
| 1999 FY | 33.3 Million USD | -31.48% |
| 1999 Q1 | 40.6 Million USD | -16.46% |
| 1998 Q2 | 46.6 Million USD | -1.06% |
| 1998 Q1 | 47.1 Million USD | -5.42% |
| 1998 Q3 | 49.9 Million USD | 7.08% |
| 1998 FY | 48.6 Million USD | -2.41% |
| 1998 Q4 | 48.6 Million USD | -2.61% |
| 1997 Q3 | 30.4 Million USD | 65.22% |
| 1997 Q1 | 24.2 Million USD | 248.2% |
| 1997 FY | 49.8 Million USD | 3457.14% |
| 1997 Q2 | 18.4 Million USD | -23.97% |
| 1997 Q4 | 49.8 Million USD | 63.82% |
| 1996 Q4 | 6.95 Million USD | 0.0% |
| 1996 FY | 1.4 Million USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Journey Medical Corporation | 76.84 Million USD | -19.62% |
| ANI Pharmaceuticals, Inc. | 904.42 Million USD | 89.836% |
| Aquestive Therapeutics, Inc. | 57.41 Million USD | -60.101% |
| Pacira BioSciences, Inc. | 1.57 Billion USD | 94.161% |
| Sunshine Biopharma, Inc. | 27.34 Million USD | -236.151% |
| Sunshine Biopharma, Inc. | 27.34 Million USD | -236.151% |
| SCYNEXIS, Inc. | 128.41 Million USD | 28.412% |
| Safety Shot Inc | 12.7 Million USD | -623.312% |
| Alpha Teknova, Inc. | 128.58 Million USD | 28.51% |
| Collegium Pharmaceutical, Inc. | 1.14 Billion USD | 91.96% |
| Bright Green Corporation | 17.4 Million USD | -428.224% |
| Dynavax Technologies Corporation | 997.09 Million USD | 90.781% |
| Esperion Therapeutics, Inc. | 205.79 Million USD | 55.331% |
| Cosmos Health Inc. | 66.29 Million USD | -38.662% |
| PainReform Ltd. | 9.93 Million USD | -825.75% |
| China SXT Pharmaceuticals, Inc. | 23.12 Million USD | -297.487% |
| Embecta Corp. | 1.21 Billion USD | 92.43% |
| Intra-Cellular Therapies, Inc. | 728.29 Million USD | 87.378% |
| Procaps Group, S.A. | 460.18 Million USD | 80.024% |
| Theratechnologies Inc. | 77.76 Million USD | -18.205% |
| Harrow Health, Inc. | 311.75 Million USD | 70.513% |
| Sonoma Pharmaceuticals, Inc. | 14.89 Million USD | -517.25% |
| Biofrontera Inc. | 27.93 Million USD | -229.11% |
| DURECT Corporation | 45.18 Million USD | -103.428% |
| Supernus Pharmaceuticals, Inc. | 1.4 Billion USD | 93.476% |
| Cronos Group Inc. | 1.13 Billion USD | 91.895% |
| OptiNose, Inc. | 107.72 Million USD | 14.668% |
| Ironwood Pharmaceuticals, Inc. | 471.07 Million USD | 80.486% |
| Kala Pharmaceuticals, Inc. | 55.94 Million USD | -64.305% |
| RedHill Biopharma Ltd. | 23.04 Million USD | -298.865% |
| Organogenesis Holdings Inc. | 460.02 Million USD | 80.017% |
| Guardion Health Sciences, Inc. | 11.91 Million USD | -671.318% |
| Cumberland Pharmaceuticals Inc. | 81.77 Million USD | -12.413% |
| Radius Health, Inc. | 1.71 Billion USD | 94.643% |
| Universe Pharmaceuticals INC | 53.28 Million USD | -72.513% |
| Phibro Animal Health Corporation | 982.18 Million USD | 90.641% |
| Procaps Group S.A. | 460.18 Million USD | 80.024% |
| Alvotech | 950.09 Million USD | 90.324% |
| TherapeuticsMD, Inc. | 43.3 Million USD | -112.258% |
| Viatris Inc. | 47.68 Billion USD | 99.807% |
| Rockwell Medical, Inc. | 52.17 Million USD | -76.197% |
| Aytu BioPharma, Inc. | 118.09 Million USD | 22.158% |
| SIGA Technologies, Inc. | 254.83 Million USD | 63.927% |
| Tilray Brands, Inc. | 4.33 Billion USD | 97.88% |
| Lifecore Biomedical, Inc. | 273.7 Million USD | 66.413% |
| Shineco, Inc. | 84.17 Million USD | -9.204% |
| PetIQ, Inc. | 868.22 Million USD | 89.412% |
| Regencell Bioscience Holdings Limited | 8.43 Million USD | -989.413% |
| Incannex Healthcare Limited | 17.04 Million USD | -439.256% |
| Neurocrine Biosciences, Inc. | 3.25 Billion USD | 97.173% |
| Alimera Sciences, Inc. | 153.52 Million USD | 40.122% |
| Silver Spike Investment Corp. | 88.57 Million USD | -3.783% |
| Assertio Holdings, Inc. | 286.41 Million USD | 67.905% |
| Shuttle Pharmaceuticals Holdings, Inc. | 5.95 Million USD | -1444.541% |
| Petros Pharmaceuticals, Inc. | 33.79 Million USD | -172.007% |
| Clever Leaves Holdings Inc. | 31.24 Million USD | -194.232% |
| Cyclo Therapeutics, Inc. | 13.24 Million USD | -593.918% |
| Avadel Pharmaceuticals plc | 261.12 Million USD | 64.796% |
| Hempacco Co., Inc. | 18.04 Million USD | -409.486% |
| Talphera, Inc. | 20.39 Million USD | -350.733% |
| Alvotech | 950.09 Million USD | 90.324% |
| Eagle Pharmaceuticals, Inc. | 406.16 Million USD | 77.367% |
| Lantheus Holdings, Inc. | 1.65 Billion USD | 94.433% |
| Currenc Group, Inc. | 141.49 Million USD | 35.03% |
| Kamada Ltd. | 351.96 Million USD | 73.882% |
| Indivior PLC | 1.95 Billion USD | 95.289% |
| Evoke Pharma, Inc. | 7.06 Million USD | -1200.508% |
| Flora Growth Corp. | 23.62 Million USD | -289.093% |
| Cyclo Therapeutics, Inc. | 13.24 Million USD | -593.918% |
| Evolus, Inc. | 188.99 Million USD | 51.361% |
| HUTCHMED (China) Limited | 1.27 Billion USD | 92.817% |
| Amphastar Pharmaceuticals, Inc. | 1.51 Billion USD | 93.924% |
| Akanda Corp. | 8.83 Million USD | -939.899% |